SEARCH

SEARCH BY CITATION

REFERENCES

  • Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. 1999. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13: 295306.
  • Baharvand H, Ashtiani SK, Taee A, Massumi M, Valojerdi MR, Yazdi PE, Moradi SZ, Farrokhi A. 2006. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Dev Growth Differ 48: 117128.
  • Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. 2004. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54: 131149.
  • Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V. 2000. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536540.
  • Brader S, Eccles SA. 2004. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 28.
  • Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 70117026.
  • Brantley-Sieders DM, Chen J. 2004. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 7: 1728.
  • Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. 2004. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 117: 20372049.
  • Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. 2005. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 19: 18841886.
  • Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. 2006. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66: 1031510324.
  • Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. 2002. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 28402847.
  • Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oostuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de GA, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E. 1999. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147157.
  • Carter N, Nakamoto T, Hirai H, Hunter T. 2002. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 4: 565573.
  • Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, Penn J. 2006. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res 82: 664673.
  • Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J. 2002. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 211.
  • Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, Reith A, Jackson D, Chen J. 2003. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5: 445456.
  • Conway EM, Collen D, Carmeliet P. 2001. Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507521.
  • Cowley S, Paterson H, Kemp P, Marshall CJ. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841852.
  • Cox BD, Natarajan M, Stettner MR, Gladson CL. 2006. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 99: 3552.
  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949954.
  • Dejana E, Bazzoni G, Lampugnani MG. 1999. Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res 252: 1319.
  • Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. 2007. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170: 115.
  • Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. 2004a. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 14481456.
  • Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. 2004b. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 320: 10961102.
  • Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. 1995. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 55: 25282532.
  • Eph Nomenclature Committee. 1997. Unified Nomenclature for the Eph family of receptors and their ligands, the ephrins. Cell 90: 403404.
  • Flenniken AM, Gale NW, Yancopoulos GD, Wilkinson DG. 1996. Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. Dev Biol 179: 382401.
  • Folberg R, Rummelt V, Parys-van GR, Hwang T, Woolson RF, Pe'er J, Gruman LM. 1993. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100: 13891398.
  • Folkman J. 1995. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 17571763.
  • Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. 2001. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230: 151160.
  • Gerety SS, Wang HU, Chen ZF, Anderson DJ. 1999. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4: 403414.
  • Giehl K. 2005. Oncogenic Ras in tumour progression and metastasis. Biol Chem 386: 193205.
  • Gray-Schopfer VC, da Rocha DS, Marais R. 2005. The role of B-RAF in melanoma. Cancer Metastasis Rev 24: 165183.
  • guirre Ghiso JA. 2002. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21: 25132524.
  • Han NM, Fleming RY, Curley SA, Gallick GE. 1997. Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation. Ann Surg Oncol 4: 264268.
  • Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP, Schlaepfer DD. 2001. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 61: 70797090.
  • Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. 2002. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J 21: 62896302.
  • Hendrix MJ, Seftor EA, Hess AR, Seftor RE. 2003. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411421.
  • Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. 2001. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 80188023.
  • Henkemeyer M, Orioli D, Henderson JT, Saxton TM, Roder J, Pawson T, Klein R. 1996. Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Cell 86: 3546.
  • Hess AR, Hendrix MJ. 2006. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 5: 478480.
  • Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, Hendrix MJ. 2001. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61: 32503255.
  • Hess AR, Seftor EA, Seftor RE, Hendrix MJ. 2003. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 47574762.
  • Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. 2005. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 65: 98519860.
  • Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. 2006. VE-Cadherin Regulates EphA2 in Aggressive Melanoma Cells Through a Novel Signaling Pathway: Implications for Vasculogenic Mimicry. Cancer Biol Ther 5: 228233.
  • Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. 2006. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol 26: 48304842.
  • Jones EA, le NF, Eichmann A. 2006. What determines blood vessel structure? Genetic prespecification vs. hemodynamics. Physiology (Bethesda) 21: 388395.
  • Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, Kajimura M, Hanai H, Tanaka M, Sugimura H. 2004. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95: 136141.
  • Kinch MS, Moore MB, Harpole DH, Jr. 2003. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613618.
  • Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, Watanabe I, Heike Y, Togashi K, Konishi J, Brechbiel MW, Wakasugi H. 2002. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res 62: 860866.
  • Krull CE, Lansford R, Gale NW, Collazo A, Marcelle C, Yancopoulos GD, Fraser SE, Bronner-Fraser M. 1997. Interactions of Eph-related receptors and ligands confer rostrocaudal pattern to trunk neural crest migration. Curr Biol 7: 571580.
  • Landen CN Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 69106918.
  • Landen CN Jr., Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. 2006. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98: 15581570.
  • Lazarova P, Wu Q, Kvalheim G, Suo Z, Haakenstad KW, Metodiev K, Nesland JM. 2006. Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int J Immunopathol Pharmacol 19: 4956.
  • Lickliter JD, Smith FM, Olsson JE, Mackwell KL, Boyd AW. 1996. Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases. Proc Natl Acad Sci USA 93: 145150.
  • Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. 2007. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109: 332340.
  • Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS. 2002. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62: 54705475.
  • Liu DP, Wang Y, Koeffler HP, Xie D. 2007. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol 30: 865871.
  • Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111118.
  • Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. 1999. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739752.
  • Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966970.
  • Maung K, Easty DJ, Hill SP, Bennett DC. 1999. Requirement for focal adhesion kinase in tumor cell adhesion. Oncogene 18: 68246828.
  • McBride JL, Ruiz JC. 1998. Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech Dev 77: 201204.
  • Mellitzer G, Xu Q, Wilkinson DG. 1999. Eph receptors and ephrins restrict cell intermingling and communication. Nature 400: 7781.
  • Miao H, Burnett E, Kinch M, Simon E, Wang B. 2000. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 6269.
  • Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. 2001. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3: 527530.
  • Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. 2006. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metast 23: 357365.
  • Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. 2000. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 275: 1938219388.
  • Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19: 60436052.
  • Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda Y, Yoshimura N. 2006. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168: 331339.
  • Orioli D, Henkemeyer M, Lemke G, Klein R, Pawson T. 1996. Sek4 and Nuk receptors cooperate in guidance of commissural axons and in palate formation. EMBO J 15: 60356049.
  • Orsulic S, Kemler R. 2000. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 113: 17931802.
  • Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, Cance WG. 1996. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 3: 100105.
  • Pandey A, Lazar DF, Saltiel AR, Dixit VM. 1994. Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J Biol Chem 269: 3015430157.
  • Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. 1995. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268: 567569.
  • Park S, Frisen J, Barbacid M. 1997. Aberrant axonal projections in mice lacking EphA8 (Eek) tyrosine protein kinase receptors. EMBO J 16: 31063114.
  • Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, Pezzella F. 2002. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 86: 244249.
  • Pratt RL, Kinch MS. 2002. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 21: 76907699.
  • Pratt RL, Kinch MS. 2003. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol Cancer Res 1: 10701076.
  • Qi JH, Claesson-Welsh L. 2001. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 263: 173182.
  • Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y, Hendrix MJ. 2003. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63: 53815389.
  • Schlaepfer DD, Hauck CR, Sieg DJ. 1999. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71: 435478.
  • Schneider GB, Kurago Z, Zaharias R, Gruman LM, Schaller MD, Hendrix MJ. 2002. Elevated focal adhesion kinase expression facilitates oral tumor cell invasion. Cancer 95: 25082515.
  • Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, Hendrix MJ. 2002. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44: 1727.
  • Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ. 2001. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61: 63226327.
  • Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB, Lubaroff DM, Hendrix MJ. 2002. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50: 189201.
  • Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL. 2005. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169: 941952.
  • Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA, Jr., Anderson DJ. 2001. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 230: 139150.
  • Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F. 2002. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 99: 821828.
  • Smith A, Robinson V, Patel K, Wilkinson DG. 1997. The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells. Curr Biol 7: 561570.
  • Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. 2002. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1: 661664.
  • Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJC. 2004. Biological signifiance of FAK in ovarian cancer: Role in migration and invasion. Am J Pathol 165: 10871095.
  • Straume O, Akslen LA. 2002. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160: 10091019.
  • Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. 2004. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 51455150.
  • Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S. 1996. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68: 164171.
  • van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW. 2005. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65: 1152011528.
  • Vanhaesebroeck B, Waterfield MD. 1999. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239254.
  • Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. 1999. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275280.
  • Wang HU, Anderson DJ. 1997. Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron 18: 383396.
  • Wang HU, Chen ZF, Anderson DJ. 1998. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741753.
  • Winslow JW, Moran P, Valverde J, Shih A, Yuan JQ, Wong SC, Tsai SP, Goddard A, Henzel WJ, Hefti F,. 1995. Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron 14: 973981.
  • Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. 1999. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629638.
  • Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 23012306.
  • Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. 2003. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163: 22712276.
  • Zhang S, Zhang D, Sun B. 2007. Vasculogenic mimicry: Current status and future prospects. Cancer Lett. [in press]
  • Zhong TP, Childs S, Leu JP, Fishman MC. 2001. Gridlock signalling pathway fashions the first embryonic artery. Nature 414: 216220.